AAD 2026: Toward Precision Medicine in Psoriasis – What It Means for Patients
In this overview, Lars Werner, CEO of the Danish Psoriasis Association, reflects on the key takeaways from AAD 2026 and shares his perspective on how precision medicine, biomarkers, and new systemic treatments are reshaping psoriasis care and changing the understanding of psoriasis as a complex inflammatory disease.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
